间皮素
表位
抗体
抗原
聚糖
单克隆抗体
分子生物学
化学
生物
糖蛋白
免疫学
作者
Jingyu Zhan,Dong Lin,Sandra Acosta,Lothar Esser,Wai Kwan Tang,Alex Zhang,Xiufen Liu,Raffit Hassan,Anne Gleinich,Asif Shajahan,Parastoo Azadi,Ira Pastan,Di Xia
出处
期刊:Cancer research communications
日期:2023-02-01
卷期号:3 (2): 175-191
被引量:5
标识
DOI:10.1158/2767-9764.crc-22-0306
摘要
The tumor-associated antigen mesothelin is expressed at high levels on the cell surface of many human cancers, while its expression in normal tissues is limited. The binding of mesothelin to the tumor-associated cancer antigen 125 (CA-125) can lead to heterotypic cell adhesion and tumor metastasis within the pleural and peritoneal cavities. Immunotherapeutic strategies targeting mesothelin are being intensively investigated. Here, we report the crystal structures of mesothelin that reveal a compact, right-handed solenoid consisting of 24 short helices and connecting loops. These helices form a nine-layered spiral coil that resembles ARM/HEAT family proteins. Glycan attachments have been identified in the structure for all three predicted N-glycosylation sites and confirmed with samples from cell culture and patient ascites. The structures of full-length mesothelin and its complex with the Fab of MORAb-009 reveal the interaction of the antibody with the complete epitope, which has not been reported previously. The N-terminal half of mesothelin is conformationally rigid, suitable for eliciting specific antibodies, whereas its C-terminal portion is more flexible. The structure of the C-terminal shedding-resistant fragment of mesothelin complexed with a mAb 15B6 displays an extended linear epitope and helps explain the protection afforded by the antibody for the shedding sites. Significance: The structures of full-length mesothelin and its complexes with antibodies reported here are the first to be determined experimentally, providing atomic models for structural organization of this protein and its interactions with antibodies. It offers insights into the function of mesothelin and guidance for further development of therapeutic antibodies.
科研通智能强力驱动
Strongly Powered by AbleSci AI